CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 553 enrolled
Drug / intervention
Systemic oncological treatmentdrug
Likely dose
Not stated in record
Key inclusion· 4
  • Age 18 to 70 years
  • Lung cancer stages IB to IV
  • Received systemic oncological treatment for at least 3 months or in follow-up after ≥3 months treatment with stable/responding disease
  • ECOG performance status ≤2
Key exclusion· 2
  • Uncontrolled comorbidities (renal failure, cardiovascular disease, etc.)
  • Physical disability or cognitive impairment preventing completion of electronic data collection

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06018376
NCT06018376N/ACompleted

Characteristics of Sexual Dysfunction in Patients With Lung Cancer

Fundación GECP·observational·Posted Aug 30, 2023·Updated Feb 6, 2026

In Brief

An observational study evaluating Systemic oncological treatment for Lung Cancer and Sexual Dysfunction. Completed, enrolled 553 participants across 29 sites in 5 countries.

Detailed Summary

The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Colombia, Peru, Portugal, Spain
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedAug 30, 2023
Enrollment StartJul 13, 2023
Primary CompletionFeb 29, 2024
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.8 years ago

Interventions

Systemic oncological treatmentdrug

Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months